BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack) vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack)
The complete healing triad combining the Wolverine Stack with GHK-Cu (copper peptide) for comprehensive tissue repair. This blend addresses healing at multiple levels: cellular repair, collagen synthesis, and tissue regeneration.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack) | Liraglutide |
|---|---|---|
| Mechanism | BPC-157 promotes angiogenesis and growth factor expression. TB-500 enhances cell migration and reduces inflammation. GHK-Cu activates genes involved in tissue remodeling, stimulates collagen and elastin production, and provides antioxidant protection. Together they support healing from multiple angles. | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. |
| Typical Dosage | Typical protocol: BPC-157 250-500mcg daily, TB-500 2-2.5mg twice weekly, GHK-Cu 1-2mg daily or applied topically for skin applications. | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. |
| Administration | BPC-157 and TB-500 via subcutaneous injection. GHK-Cu can be injected subcutaneously or used topically depending on the target area. Systemic and local administration may be combined. | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. |
| Side Effects | Generally well-tolerated. Possible injection site irritation, mild fatigue, or temporary skin discoloration with GHK-Cu. | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. |
| Best For |